Last reviewed · How we verify
NCT05446948
Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy
NA trial testing beveled 27G+ vitrectomy system in Proliferative Diabetic Retinopathy in 52 participants. Completed in 1 June 2023.
1 June 2023
Quick facts
| Lead sponsor | Tianjin Medical University Eye Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 11 July 2022 |
| Primary completion | 1 June 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- beveled 27G+ vitrectomy system
- standard 25G+ vitrectomy system
Conditions studied
- Proliferative Diabetic Retinopathy — all drugs for Proliferative Diabetic Retinopathy →
- Vitrectomy — all drugs for Vitrectomy →
Sponsor
Tianjin Medical University Eye Hospital
Who can join
Eligibility, any sex, with Proliferative Diabetic Retinopathy or Vitrectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In recent years, vitrectomy has moved toward a minimally invasive vitrectomy surgery (MIV) system, which could effectively reduce the occurrence of operation complications, while reducing the time of post-operation recovery. With an improved design of bevel tip and a high cutting rate capacity of 10000cpm, Advanced ULTRAVIT® probes potentially provide an strong technical support for the application of MIV. The new probe facilitates great control during delicate surgical maneuvers, such as separating the hyaloid from the retinal surface, dissecting fibrovascular tissue off the surface of retina. However, there was no sufficient clinical evidence to support the benefits of Advanced ULTRAVIT ® probes in the complicated vitreoretinal surgery, such as proliferative diabetic retinopathy. More importantly, there is an urgent need of clinical evidence to support 10000cpm launch and conversion which is major objective of 2021 VR growth strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05446948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Proliferative Diabetic Retinopathy
Currently open trials in the same condition.
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Tianjin Medical University Eye Hospital trials
Trials by the same sponsor.
- NCT07494799 — Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear · not yet recruiting
- NCT07449247 — PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention · Phase 1, PHASE2 · not yet recruiting
- NCT05728476 — Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Dia · NA · recruiting
- NCT05990829 — Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed · Phase 4 · unknown
- NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05446948 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Eye Hospital
- Last refreshed: 6 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05446948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing